Influence of ORM1, PXR, CAR, CYP3A4 and CYP3A5 gene polymorphisms in mediating susceptibility risk to chronic myeloid leukaemia and response to imatinib mesylate therapy
Genetic polymorphisms are well recognized sources of individual differences in disease risk and treatment response. Associations between human genetic variants and predisposition to diseases and adverse events for different kinds of drug interactions with hundreds of protein like receptors, trans...
Main Author: | Maddin, Najlaa |
---|---|
Format: | Thesis |
Language: | English |
Published: |
2017
|
Subjects: | |
Online Access: | http://eprints.usm.my/43138/1/Dr._Najlaa_Maddin-24_pages.pdf |
Similar Items
-
Association of CYP3A5*3, CYP3A4*18 & CYP2B6*6 polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
by: Chingiz Asadov, et al.
Published: (2023-01-01) -
An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia
by: Bee, P.C., et al.
Published: (2012) -
Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01) -
OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01) -
Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.